Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (Weighted Average) (2016 - 2025)

Zevra Therapeutics' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $55.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 19.59% year-over-year to $55.3 million; the TTM value through Dec 2025 reached $55.3 million, up 19.59%, while the annual FY2025 figure was $55.3 million, 19.59% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $55.3 million in Q4 2025 per ZVRA's latest filing, up from $54.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $55.3 million in Q4 2025 to a low of $4.3 million in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $34.8 million, with a median of $34.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 87.67% in 2023, then soared 1024.25% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $29.8 million in 2021, then grew by 15.87% to $34.5 million in 2022, then increased by 2.79% to $35.5 million in 2023, then soared by 30.46% to $46.3 million in 2024, then grew by 19.59% to $55.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Shares Outstanding (Weighted Average) are $55.3 million (Q4 2025), $54.9 million (Q3 2025), and $54.8 million (Q2 2025).